Pfizer

Strategic intent

Pfizer is a global biopharmaceutical giant focused on the discovery, development, manufacture, and commercialization of innovative medicines, vaccines, and therapies across oncology, primary care, specialty care, and immunology.

Key market signals

• 2026-10: Pfizer announced detailed Phase 2 data for its investigational 25-valent pediatric pneumococcal conjugate vaccine candidate (PF-07872412) showing robust immune responses and comparable safety to Prevnar 20.
• 2026-10: Pfizer initiated workforce layoffs at its Rocky Mount and Sanford manufacturing facilities in North Carolina as part of its ongoing multibillion-dollar cost-cutting initiative.
• 2026-10: Pfizer's TUKYSA regimen received FDA approval as a front-line maintenance treatment for HER2-positive metastatic breast cancer.
• 2026-08: Pfizer's Chief Financial Officer Dave Denton stepped down to pursue an opportunity outside the pharma industry, with Cecile Guegan appointed as Interim CFO.
• 2026-06: Pfizer reached a global settlement in principle to resolve approximately 80% of the federal Depo-Provera meningioma lawsuits (MDL 3140).

Financial health

• For the full-year 2025, Pfizer reported revenues of $62.6 billion, representing a 2% year-over-year operational decline, with reported diluted EPS of $1.36 and adjusted diluted EPS of $3.22 (https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGIkGICjIfEwkPHPF3r75UBk09vLCbtCkaBrjcT0Ave8Rxv9fCVGvJ95Itg64DOQXjRAfBKYDRnaJ8dHszCJpYGvTrRlUV80snE2hI8uLI2q7P2yz0PAAErJnBkEyUR35AM_2Yrh3ePsLd2Xur1ka-CHjzaOi-Df9MbeVr1DMtFUVNrtxgqFva_vKzmFRNle3KT563I9uzIwfQ=).
• For Q2 2026, Pfizer reported revenue of $15.03 billion, up 2.6% year-over-year, but posted a net loss of $248 million due to $4.33 billion in asset impairments (https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGCQarBFKp9H8cOf-3ssbu-P0KzB7ArbESPwwJ9nUh0MR5H_FbMv3Hjv7SxMOwS31MifvrNE2C2hxrEh7In9rW0MWZuY3JpKQtFECn5WRREf9rrAVeO31xtvXQJLdCv5EpQZQDvayPVULMz3vh6hT5p94zCpEMTXUILHdoWWh-HPkdo1l7yP8CYSBnjKtwEQKbrGdb_pDNmjIDIesEydSPIieqNsR__0Sd8GRZZRIPS_Uk9xdzq3Jt-J59Vq-2JwphJE6pdD4Y=).
• Pfizer reaffirmed its full-year 2026 financial guidance with expected revenues in the range of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00 (https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGIkGICjIfEwkPHPF3r75UBk09vLCbtCkaBrjcT0Ave8Rxv9fCVGvJ95Itg64DOQXjRAfBKYDRnaJ8dHszCJpYGvTrRlUV80snE2hI8uLI2q7P2yz0PAAErJnBkEyUR35AM_2Yrh3ePsLd2Xur1ka-CHjzaOi-Df9MbeVr1DMtFUVNrtxgqFva_vKzmFRNle3KT563I9uzIwfQ=).

Impact & compliance

Legal & risks

In January 2025, Pfizer agreed to pay $59.7 million on behalf of its subsidiary Biohaven to resolve Department of Justice allegations of violating the Anti-Kickback Statute and False Claims Act. In May 2026, Paul Nakamura filed a class action lawsuit alleging that Pfizer's website tracked visitors […]

Forensic audit — 3 findings

• ⚠ In October 2025, the New Jersey Department of Environmental Protection sued Pfizer and others over toxic waste and groun...
• ⚠ In July 2026, Pfizer reached a $44 million class action settlement to resolve allegations that it manufactured and sold
• ⚠ In July 2026, the U.S. Court of Appeals for the District of Columbia Circuit vacated a district court's dismissal of a l...

🔒 Proprietary analysis

Proprietary Analysis — available with full access

Want the full analysis?

Get access to strategic fit scoring, cultural fit analysis, full forensic detail, and alignment dimensions.